Oral lichen planus (OLP) is a chronic inflammatory disease with different clinical presentations that can be classified as reticular or atrophic-erosive. Sixty-two OLP patients were studied to ...

OSAKA, Japan & WALTHAM, Mass., December 06, 2025--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ...

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

Late-breaking oral presentation of interim safety and efficacy data from the phase 1 study of SBT-77-7101, including a favorable early safety profile, with preliminary clinical and mechanistic ...

WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative ...

For presentations scheduled prior to 1:00 PM, please go to the SHED Atrium between 8:00 and 8:30 AM and load your final presentation. For presentations scheduled after 1:00 PM, please go to the SHED ...

Individual presentation times are noted in your formal invitation and on the Speaker Center website. A question-and-answer panel will be held for all session participants at the end of the ...

Please provide your email address to receive an email when new articles are posted on . Mid- to late-career medical oncologists from NCI-designated cancer centers delivered a high percentage of oral ...